Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

J.R. Passweg , M. Labopin , M. Christopeit , J. Cornelissen , T. Pabst , G. Socié , N. Russel , I. Yakoub-Agha , D. Blaise (1) , T. Gedde-Dahl , H. Labussière-Wallet , R. Malladi , E. Forcade , S. Maury , E. Polge , F. Lanza , N.C. Gorin , M. Mohty , A. Nagler

1 CRCM - Centre de Recherche en Cancérologie de Marseille

Domaines: Immunologie

J.R. Passweg, M. Labopin, M. Christopeit, J. Cornelissen, T. Pabst, et al.. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Biology of Blood and Marrow Transplantation, 2020, 26 (4), pp.659-664. ⟨10.1016/j.bbmt.2019.11.021⟩. ⟨hal-03152838⟩